News Johnson & Johnson Bulgaria S.E.

Equities

JNJ

US4781601046

Real-time Estimate Tradegate Other stock markets 20:59:51 23/05/2024 BST			5-day change	1st Jan Change
138.5 ^EUR	-1.11%		+1.01%	-11.86%

08:03pm	Some of the biggest splits in Corporate America	RE
05-22	Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Some of the biggest splits in Corporate America	07:03pm	RE
Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies	05-22	RE
Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says	05-22	MT
Top Midday Stories: US Targets August 1 Start Date for China Tariff Hikes; CFPB Says BNPL Requires Credit Card-Level Oversight; Target Shares Fall on Earnings Miss; Third BHP Bid Rejected by Anglo American	05-22	MT
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	05-22	BU
Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says	05-22	MT
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	05-22	AQ
Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship	05-21	MT
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission	05-21	AQ
Novel biologic could offer ulcerative colitis symptomatic remission	05-21	AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	05-21	AQ
J&J: positive trial for Tremfya in ulcerative colitis	05-21	CF
Valneva Names New Chief Scientific Officer	05-21	MT
Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft...	05-20
Ex-dividend day	05-19	FA
J&J-backed startup Rapport files for US IPO	05-17	RE
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Transcript	05-17	PU
J&J-Linked Rapport Therapeutics Files For IPO	05-17	DJ
J&J: towards acquisition of Proteologix for $850 million	05-17	CF
Johnson & Johnson to Buy Proteologix For $850 Million in Cash	05-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm